A new educational program in heart failure drug development: the Brescia international master program.

Area of Science:

• Cardiology
• Clinical Trials
• Medical Education

Background:

• Acute heart failure prognosis remains poor, with high rehospitalization rates and limited therapies for preserved ejection fraction.
• Past heart failure clinical trials have yielded disappointing results, highlighting the need for innovative drug and device development approaches.
• Current drug development often lacks alignment between drug mechanisms and clinical events, necessitating improved strategies.

Purpose of the Study:

• To propose a structured training program for 'drug development in Heart Failure'.
• To enhance the matching of drug mechanisms with heart failure pathophysiology, aiming to reduce mortality and rehospitalization.
• To introduce a novel educational and mentorship program for researchers in heart failure drug development.

Main Methods:

• The proposed program emphasizes in-depth training on heart failure pathophysiology.
• Physicians will learn to align drug mechanisms of action with specific clinical events and disease mechanisms.
• Applicants require proven qualifications and a demonstrated interest in heart failure drug development.

Main Results:

• The article serves as a roadmap for implementing innovative drug development processes in heart failure.
• It advocates for a new educational framework and mentorship for early-career researchers.
• The proposed training aims to equip future leaders with systematic drug development expertise.

Conclusions:

• A systematic training program is crucial for advancing heart failure drug development.
• Improving the understanding of pathophysiology in clinical trials can lead to more effective therapies.
• Investing in the education of new generations of scientists is vital for future breakthroughs in heart failure treatment.